Musculoskeletal Symptoms in Post Acute Covid-19 Patients

Covid19 Clinical Trial

Official title:

Musculoskeletal Symptoms and Related Factors in Post Acute Covid-19 Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04932889
• Other study ID #: EskisehirCityH
• Status: Completed
• Start date: June 11, 2021
• Est. completion date: June 14, 2021

Study information

• Verified date: June 2021
• Source: Eskisehir City Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The patients whose musculoskeletal symptoms initiated or aggravated with Covid-19, were compared with the patients whose musculoskeletal symptoms did not change with Covid-19. The variables; the demographic and treatment datas, admission symptoms, post acute-Covid-19 symptoms, laboratory, chest computed tomography findings.

Description:

There is a lack of an overview of the factors associated with post acute-Covid-19 musculoskeletal symptoms. The aims are;1-to evaluate the most frequent admission symptoms and the frequency of musculoskeletal symptoms in post acute-Covid-19 patients,2-to determine the related factors with the post acute-Covid-19 musculoskeletal symptoms.

In this retrospective study; the patients whose musculoskeletal symptoms initiated or aggravated with Covid-19, were compared wthe patients whose musculoskeletal symptoms did not change with Covid-19. The variables; the demographic and treatment datas, admission symptoms, post acute-Covid-19 symptoms, laboratory (complete blood count, C-reactive protein, ferritin, D-dimer), chest computed tomography findings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 280
• Est. completion date: June 14, 2021
• Est. primary completion date: June 13, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Being 18 years or older

• Having Covid-19 treatment (home quarantine / hospital / intensive care unit) according to a positive polymerase chain reaction (PCR) test in a nasopharyngeal + oropharyngeal swab or chest CT.

Exclusion Criteria:

• Patients who did not have musculoskeletal symptom records (admission symptoms and musculoskeletal symptoms such as; fatigue, spine / joint /muscle pain/ numbness) in patients files

• Acute Covid-19 patients whose symptoms started less than 1 month

Related Conditions & MeSH terms

• Covid19
• Musculoskeletal Abnormalities

Intervention

Other:
• Survey
A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
• Laboratory parameters
The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.
• chest computed tomography
Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).

Locations

Country	Name	City	State
Turkey	Eskisehir City Hospital	Eskisehir

Sponsors (1)

Lead Sponsor	Collaborator
Eskisehir City Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of back pain	given as percentage %	Baseline
Primary	Chest computed tomography	Presence of covid-19 findings in chest computed tomography (covid findings positive or negative)	Baseline
Primary	Rate of low-back pain	given as percentage %	Baseline
Primary	Rate of fatigue	given as percentage %	Baseline
Primary	Rate of neck pain	given as percentage %	Baseline
Primary	Rate of dyspnea	given as percentage %	baseline
Primary	Rate of joint pain	given as percentage %	Baseline
Primary	Rate of chest pain	given as percentage %	Baseline
Primary	Rate of myalgia	given as percentage %	Baseline
Secondary	age	years	Baseline
Secondary	Weight	kilograms	Baseline
Secondary	gender	female or male	Baseline
Secondary	Duration after the onset of covid-19	months	Baseline
Secondary	Lymhocyte levels	10*3 cells/microliter	Baseline
Secondary	D-dimer levels	miligram/Litre	Baseline
Secondary	C-reactive protein	miligram/Litre	Baseline
Secondary	Hemoglobin	gram/desilitre	Baseline
Secondary	Platelet	10*3 cells/microliter	Baseline
Secondary	Ferritin	nanogram/mililitre	Baseline